(Q38107101)

29 August 2017

Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity (English)

1 reference

29 August 2017

Daniel L Hertz

1

1 reference

PubMed ID

23677053

29 August 2017

Howard L McLeod

series ordinal

2

1 reference

29 August 2017

16 May 2013

1 reference

Journal of Human Genetics

29 August 2017

1 reference

29 August 2017

58

1 reference

29 August 2017

346-352

1 reference

29 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/jhg.2013.42

29 August 2017

0 references

cites work

Cancer pharmacogenomics: early promise, but concerted effort needed

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Linking abnormal mitosis to the acquisition of DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

The staging of cancer: a retrospective and prospective appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Concordance among gene-expression-based predictors for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Personalized oncology through integrative high-throughput sequencing: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Dysregulation of the TSC-mTOR pathway in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Pharmacogenomics: unlocking the human genome for better drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Systematic meta-analyses and field synopsis of genetic association studies in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Comprehensive molecular characterization of human colon and rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Association of SIPA1 545 C > T polymorphism with survival in Chinese women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Bromodomain 4 activation predicts breast cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Dosing strategies for anticancer drugs: the good, the bad and body-surface area

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Peripheral neuropathy induced by microtubule-stabilizing agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Microtubule dynamics: taking aim at a moving target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Do beta-tubulin mutations have a role in resistance to chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Mutations in FGD4 encoding the Rho GDP/GTP exchange factor FRABIN cause autosomal recessive Charcot-Marie-Tooth type 4H

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

Assembly of microtubules at the tip of growing axons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

7 January 2021

SPA-1 controls the invasion and metastasis of human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

7 January 2021

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

7 January 2021

UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

7 January 2021

UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

7 January 2021

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

7 January 2021

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

7 January 2021

The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

7 January 2021

Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

7 January 2021

A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28

1 reference

https://api.crossref.org/works/10.1038%2FJHG.2013.42

7 January 2021

Identifiers

DOI

10.1038/JHG.2013.42

1 reference

29 August 2017

1 reference

PubMed ID

23677053